Sichuan Kelun Pharmaceutical Co., Ltd.

002422

CNE100000PW7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 16/07/2024 BST			5-day change	1st Jan Change
31.7 ^CNY	-0.03%		+3.32%	+9.12%

07-02	Kelun-Biotech to Buy Equipment from Affiliate	MT
07-02	Kelun-Biotech to Buy Equipment from Sichuan Kelun Pharmaceutical's Unit	MT

Tranche Update on Sichuan KELUN PHARMACEUTICAL Co., Ltd.'s Equity Buyback Plan announced on May 12, 2017.

January 02, 2018

From May 11, 2017 to December 31, 2017, the company has repurchased 2,163,116 shares, representing 0.15% for CNY 33.32 million. With this, the company has completed the repurchase of 2,163,116 shares, representing 0.15% for CNY 33.32 million under the buyback announced on May 12, 2017.

Latest news about Sichuan Kelun Pharmaceutical Co., Ltd.

Kelun-Biotech to Buy Equipment from Affiliate	07-02	MT
Kelun-Biotech to Buy Equipment from Sichuan Kelun Pharmaceutical's Unit	07-02	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024	05-22	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	04-24	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-10	CI
US FDA to Accelerate Review of Kelun Pharma Unit's Lung Cancer Drug	03-12	MT
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%	01-23	MT
Kelun Pharmaceutical's Olaparib Tablets Get Nod from Chinese Drug Regulator	01-22	MT
Kelun Pharma Gets Registration Approval in China for Immune Thrombocytopenia Drug	01-17	MT
Kelun Pharma Sees Up to 50% Jump in 2023 Profit	01-16	MT
Kelun Pharma's Unit Gets US FDA's Orphan Drug Designation to A400	11-28	MT
Kelun Pharmaceutical's Unit Gains Registration Certificate for Ceftazidime Avibactam Sodium/Sodium Chloride Injection	11-01	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/10/23	CI
Kelun Pharma Ends Cancer Drug Contract, Revises Partnership With Merck	24/10/23	MT
Global markets live: Foxconn, Roche, Eli Lilly, Chevron, Apple...	23/10/23
The good, the bad and the ugly	23/10/23
Merck discontinues some cancer drug development with China's Sichuan Kelun	23/10/23	RE
Kelun Pharma Unit Obtains Registration Approval in China for Bacterial Infection Drug	18/10/23	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Sichuan Kelun Pharma to Start License Application Process For New Cancer Drug	15/08/23	MT
Kelun Pharma's Unit Gets Gadobutrol injection Certified	13/07/23	MT
Kelun Pharma Expects Up to 66% Jump in H1 Profit	05/07/23	MT
China's Sichuan Kelun-Biotech opens books for $208 million Hong Kong IPO - term sheet	28/06/23	RE
Kelun Pharma Registers GERD Drug in China	27/06/23	MT

Chart Sichuan Kelun Pharmaceutical Co., Ltd.

Duration

Period

Chart Sichuan Kelun Pharmaceutical Co., Ltd.

More charts

Company Profile

Sichuan Kelun Pharmaceutical Co., Ltd. specializes in developing, manufacturing and marketing pharmaceuticals. Net sales break down by activity as follows: - manufacturing and sale of pharmaceutical products (98%). Net sales break down by family of products between injectable drugs (56.9%) and other (43.1%; tablets, capsules, granules, etc.); - other (2%). China accounts for 94.6% of net sales.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Sichuan Kelun Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.71 CNY

Average target price

42.04 CNY

Spread / Average Target

+32.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SICHUAN KELUN PHARMACEUTICAL CO., LTD.	+9.12%	6.94B
ELI LILLY AND COMPANY	+57.64%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.50%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+12.45%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.17%	179B
PFIZER, INC.	+3.27%	167B

Other Pharmaceuticals

Sichuan Kelun Pharmaceutical Co., Ltd.

Equities

002422

CNE100000PW7

Pharmaceuticals

Tranche Update on Sichuan KELUN PHARMACEUTICAL Co., Ltd.'s Equity Buyback Plan announced on May 12, 2017.

EPS Revisions